Page 90 - Read Online

Sharma et al. Cancer Drug Resist 2023;6:688-708 https://dx.doi.org/10.20517/cdr.2023.82 Page 706

126. Sesé B, Íñiguez-Muñoz S, Ensenyat-Mendez M, et al. Glioblastoma embryonic-like stem cells exhibit immune-evasive phenotype.
Cancer 2022;14:2070. DOI PubMed PMC
127. Gaynor N, Crown J, Collins DM. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin Cancer Biol
2022;79:44-57. DOI
128. De Felice F, Marchetti C, Palaia I, et al. Immune check-point in cervical cancer. Crit Rev Oncol Hematol 2018;129:40-3. DOI
129. Zhao X, Pan X, Wang Y, Zhang Y. Targeting neoantigens for cancer immunotherapy. Biomark Res 2021;9:61. DOI PubMed PMC
130. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74. DOI PubMed
131. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer
therapy. Nat Rev Cancer 2016;16:275-87. DOI PubMed PMC
132. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21. DOI
PubMed PMC
133. Watowich MB, Gilbert MR, Larion M. T cell exhaustion in malignant gliomas. Trends Cancer 2023;9:270-92. DOI PubMed PMC
134. Yue Q, Zhang X, Ye HX, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J
Neurooncol 2014;116:251-9. DOI PubMed PMC
135. Tomaszewski WH, Waibl-Polania J, Chakraborty M, et al. Neuronal CaMKK2 promotes immunosuppression and checkpoint
blockade resistance in glioblastoma. Nat Commun 2022;13:6483. DOI PubMed PMC
136. Mieczkowski J, Kocyk M, Nauman P, et al. Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is
associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget 2015;6:33077-90. DOI PubMed PMC
137. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. Impaired capacity for upregulation of MHC class II in
tumor-associated microglia. Glia 2005;51:279-85. DOI PubMed
138. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in
mediating antitumor immune responses. Neuro Oncol 2006;8:261-79. DOI PubMed PMC
139. Beauvillain C, Donnou S, Jarry U, et al. Neonatal and adult microglia cross-present exogenous antigens. Glia 2008;56:69-77. DOI
140. Jarry U, Jeannin P, Pineau L, Donnou S, Delneste Y, Couez D. Efficiently stimulated adult microglia cross-prime naive CD8+ T cells
injected in the brain. Eur J Immunol 2013;43:1173-84. DOI PubMed
141. Lee AH, Sun L, Mochizuki AY, et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the
immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun 2021;12:6938. DOI
142. Chen AX, Gartrell RD, Zhao J, et al. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal
pro-tumor marker. Genome Med 2021;13:88. DOI PubMed PMC
143. Park JH, Kang I, Lee HK. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade. Front
Immunol 2022;13:1044544. DOI PubMed PMC
144. Simonds EF, Lu ED, Badillo O, et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune
checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer 2021;9:e002181. DOI PubMed PMC
145. Iorgulescu JB, Gokhale PC, Speranza MC, et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint
blockade in glioblastoma. Clin Cancer Res 2021;27:276-87. DOI PubMed PMC
146. Shields LB, Shelton BJ, Shearer AJ, et al. Dexamethasone administration during definitive radiation and temozolomide renders a
poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 2015;10:222. DOI PubMed PMC
147. Ueda S, Mineta T, Nakahara Y, Okamoto H, Shiraishi T, Tabuchi K. Induction of the DNA repair gene O6-methylguanine-DNA
methyltransferase by dexamethasone in glioblastomas. J Neurosurg 2004;101:659-63. DOI PubMed
6
148. Aasland D, Reich TR, Tomicic MT, Switzeny OJ, Kaina B, Christmann M. Repair gene O -methylguanine-DNA methyltransferase
is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation. J Neurochem 2018;144:139-51.
DOI
149. Huarte M. The emerging role of lncRNAs in cancer. Nat Med 2015;21:1253-61. DOI PubMed
150. Zhang R, Xia LQ, Lu WW, Zhang J, Zhu JS. LncRNAs and cancer. Oncol Lett 2016;12:1233-9. DOI PubMed PMC
151. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016;29:452-63. DOI PubMed PMC
152. Ghafouri-Fard S, Agabalazadeh A, Abak A, et al. Role of long non-coding RNAs in conferring resistance in tumors of the nervous
system. Front Oncol 2021;11:670917. DOI PubMed PMC
153. Li Z, Zhang J, Zheng H, et al. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide
resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. J Exp Clin Cancer Res
2019;38:380. DOI PubMed PMC
154. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic
activities. Nat Med 2008;14:1271-7. DOI PubMed
155. Ye X, Wei W, Zhang Z, et al. Identification of microRNAs associated with glioma diagnosis and prognosis. Oncotarget
2017;8:26394-403. DOI PubMed PMC
156. Yang J, Liu R, Deng Y, et al. MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through
targeting mTOR. Int J Cancer 2017;141:2082-92. DOI
157. Hübner M, Moellhoff N, Effinger D, et al. MicroRNA-93 acts as an “anti-inflammatory tumor suppressor” in glioblastoma.
Neurooncol Adv 2020;2:vdaa047. DOI PubMed PMC
158. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with